for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Veru Inc

VERU.OQ

Latest Trade

1.97USD

Change

0.09(+4.79%)

Volume

51,884

Today's Range

1.90

 - 

1.97

52 Week Range

1.19

 - 

2.49

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.88
Open
1.91
Volume
51,884
3M AVG Volume
3.92
Today's High
1.97
Today's Low
1.90
52 Week High
2.49
52 Week Low
1.19
Shares Out (MIL)
65.04
Market Cap (MIL)
123.57
Forward P/E
-10.00
Dividend (Yield %)
--

Next Event

Veru Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Veru Q3 Loss Per Share $0.04

Veru Announces Successful Completion Of Pre-NDA Meeting With FDA For Tadfin

Veru Reports Q2 Loss Per Share Of $0.06

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Veru Inc

Veru Inc., formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men's and women's health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector. For men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout and sexual dysfunction. Women's Health has product candidates for female sexual health, and advanced breast and ovarian cancers. It manufactures, markets and sells the FC2 Female Condom. FC2 provides dual protection against unintended pregnancy and sexually transmitted infections (STIs), including human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS).

Industry

Biotechnology & Drugs

Contact Info

48 NW 25th St Ste 102

+1.312.5959123

http://veruhealthcare.com/

Executive Leadership

Elgar Peerschke

Chairman of the Board

Mitchell S. Steiner

President, Chief Executive Officer, Director

Overton B. Parrish

Vice Chairman of the Board

Mario Eisenberger

Director

Harry Fisch

Director

Key Stats

1.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-0.220

2018

-0.440

2019(E)

-0.190
Price To Earnings (TTM)
--
Price To Sales (TTM)
4.37
Price To Book (MRQ)
3.55
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
31.59
LT Debt To Equity (MRQ)
18.18
Return on Investment (TTM)
-40.70
Return on Equity (TTM)
-31.45

Latest News

BRIEF-Veru Reports Q2 Loss Per Share $0.07

* VERU INC Q2 REVENUE $2.6 MLN VS $2.4 MLN Source text for Eikon: Further company coverage:

BRIEF-U.S. FDA Grants Fee Waiver For Tamsulosin Drs New Drug Application

* FDA GRANTS FEE WAIVER FOR TAMSULOSIN DRS NEW DRUG APPLICATION

BRIEF-Veru Says On March 5 Entered Into Credit Agreement For Synthetic Royalty Financing Transaction

* VERU SAYS ON MARCH 5, ENTERED INTO CREDIT AGREEMENT FOR SYNTHETIC ROYALTY FINANCING TRANSACTION - SEC FILING

BRIEF-Veru Q1 Loss Per Share $0.08

* REMAIN ON TRACK TO FILE WITH FDA COMPANY'S FIRST NDA FOR TAMSULOSIN DRS IN 2018

BRIEF-Veru to Present At 2018 Genitourinary Cancers Symposium

* VERU ANNOUNCES PRESENTATION OF DATA DEMONSTRATING EFFICACY OF VERU-111 IN A TAXANE RESISTANT HUMAN PROSTATE CANCER MODEL AT THE 2018 GENITOURINARY CANCERS SYMPOSIUM

BRIEF-Veru reports Q4 Loss Per Share $0.10

* VERU REPORTS FISCAL 2017 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS

BRIEF-Veru Inc Files For Non-Timely 10-K

* VERU - DUE TO TECHNICAL DIFFICULTIES AT THIRD PARTY FILING AGENT, CO'S 10-K WAS TRANSMITTED, RECEIVED FOR FILING ON EDGAR AT 5:33 PM ET ON DEC 29, 2017 Source text (http://bit.ly/2EzynHN) Further company coverage:

BRIEF-Veru Acquires Novel Proprietary Formulation For Overactive Bladder

* VERU ACQUIRES NOVEL PROPRIETARY FORMULATION FOR OVERACTIVE BLADDER

BRIEF-Veru announces Tamsulosin drs bioequivalence clinical trial results

* Veru announces Tamsulosin Drs bioequivalence clinical trial results

BRIEF-Veru files for mixed shelf of up to $50 million

* Files for mixed shelf of up to $50 million - SEC filing Source text: (http://bit.ly/2lfqJfT) Further company coverage:

BRIEF-Veru announces agreement with Timm Medical Technologies to distribute and to promote preboost

* Veru Inc announces agreement with Timm Medical Technologies LLC to distribute and to promote preboost

BRIEF-Veru Inc initiates telemedicine capability to expand access to prescriptions for FC2 female condom

* Veru Inc announces initiation of telemedicine capability to expand access to prescriptions for FC2 female condom Source text for Eikon: Further company coverage:

BRIEF-Ajwan Gulf Real Estate to acquire stake in Health Co and Emaar Food Group

* BOARD APPROVES TO COMPLETE ACQUISITION OF HEALTH CO, ACQUISITION OF 70 PERCENT STAKE IN EMAAR FOOD GROUP

BRIEF-Veru reports Q3 loss per share $0.03

* Qtrly unit sales totaled 8.5 million, which is 21 percent lower than 10.7 million from same prior-year quarter

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up